Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Merck has also decided to end the favezelimab clinical development program
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
With the addition of Karsanbhai, the Merck board will consist of 13 members
Subscribe To Our Newsletter & Stay Updated
